Allarity Therapeutics, Inc.

Allarity Therapeutics is a biotechnology company focused on precision medicine aimed at developing innovative cancer therapies, particularly stenoparib, which targets advanced recurrent ovarian cancer through a dual-action approach. Founded in 2004, Allarity Therapeutics operates from Cambridge, US, concentrating on precision medicine for cancer treatment. The company has undergone strategic pivots to enhance its product offerings and employs advanced diagnostic technologies. CEO James Cullem leads the organization, which has successfully raised USD 20.

00 mn through its latest PIPE funding round on July 10, 2023, primarily targeting the advancement of its proprietary compounds and technologies. Allarity Therapeutics specializes in precision medicine, with a primary focus on developing stenoparib, an orally available small molecule inhibitor designed for patients with advanced recurrent ovarian cancer. Stenoparib operates through a unique dual-action mechanism, targeting both PARP1/2 and telomerase maintenance enzymes, which enhances its efficacy against various cancer types beyond ovarian cancer. The company employs its proprietary Drug Response Predictor (DRP®) technology to refine patient selection, ensuring that treatments are personalized and tailored to individual tumor biology.

This innovative diagnostic platform has demonstrated its ability to predict patient responses to therapies based on extensive gene expression data from over 3,000 patient tumors. Allarity Therapeutics aims to serve a global market, with active clinical studies and product offerings primarily in the United States and Europe, targeting oncologists, hospitals, and cancer treatment centers. Allarity Therapeutics generates revenue through partnerships and clinical trial collaborations that focus on the advancement of stenoparib. The company potentially engages in B2B transactions with healthcare providers, research institutions, and pharmaceutical partners, offering its DRP® technology as a companion diagnostic to enhance treatment selection for cancer therapies.

Revenues stem from licensing agreements, research funding, and successful milestone achievements linked to the progression of their clinical trials. Additionally, revenues from services related to the DRP® platform are structured through service agreements with oncology practices that utilize the technology for patient stratification, reflecting the transactional nature prevalent in biotechnology based on clinical trial outcomes and the commercialization of stenoparib. Allarity Therapeutics is actively developing new products, particularly focusing on expanding the clinical applications of stenoparib. The recent funding of USD 20.

00 mn raised through the PIPE round in July 2023 will be utilized to propel these initiatives, including further clinical trials. The company plans to expand its market presence in Europe and the United States by enhancing its partnerships with healthcare providers and increasing its clinical study footprint. Allarity is working towards the commercialization of stenoparib and aims to introduce its innovative cancer therapies to a broader patient demographic by 2025.